Kiniksa Pharmaceuticals International, plc (KNSA)
(Delayed Data from NSDQ)
$35.77 USD
-0.79 (-2.16%)
Updated Sep 16, 2025 04:00 PM ET
After-Market: $35.74 -0.03 (-0.08%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth D Momentum B VGM
Fundamental Charts
About Return on Equity (TTM)
Kiniksa Pharmaceuticals International, plc's return on equity, or ROE, is 1.05% compared to the ROE of the Medical - Biomedical and Genetics industry of -66.95%. While this shows that KNSA makes good use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
KNSA 35.77 -0.79(-2.16%)
Will KNSA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for KNSA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KNSA
Zoetis Gains CVMP Backing for Portela, Eyes EU Approval in Cat OA Pain
RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal
KNSA: What are Zacks experts saying now?
Zacks Private Portfolio Services
TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA
RARE Reports Positive Long-Term Data From Metabolic Disorder Study
IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results
Other News for KNSA
Slingshot Bullish appears for KNSA after 1.46% move
Tracking Baker Brothers Portfolio - Q2 2025 Update
KNSA makes New 52 Week Closing High on September 12
Is KNSA positioned for a breakout? New 52 Week Closing High shows up after rising 2.15%
Is KNSA set to rally? New 52 Week High shows up after sliding 1.71%